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GRAPHICAL ABSTARCT 
 
 
Abstract 
Virus-like particles (VLPs) are potential oral vaccine candidates, as their highly compact 
structure may allow them to withstand the harsh conditions of the gastro-intestinal (GI) 
environment. Hepatitis B core antigen (HBcAg) is an immunogenic protein that assembles into 
30 or 34 nm diameter VLPs. Here, the stabilities of both the HBcAg polypeptide itself and the 
three-dimensional structure of the VLPs upon exposure to in vitro and ex vivo simulated gastric 
and intestinal fluids were investigated. Plant-expressed HBcAg VLPs were efficiently purified 
by sucrose density gradient and characterized. The purified VLPs did not show major chemical 
or physical instability upon exposure to the low pH conditions typically found in the stomach; 
however, they completely agglomerated upon acidification and subsequent pH neutralization. 
The HBcAg polypeptide was highly digested upon exposure to pepsin in simulated gastric fluids. 
HBcAg appeared more stable in both simulated and ex vivo intestinal fluids, where despite a 
partial digestion of the HBcAg polypeptide, the VLPs maintained their most immunogenic 
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epitopes and their particulate conformation. These results suggest that HBcAg VLPs are likely to 
be unstable in gastric fluids, yet if the gastric instability could be bypassed, they could maintain 
their particulate structure and immunogenicity in intestinal fluids. 
 
Keywords: HBcAg; VLPs; oral delivery; proteins; gastrointestinal fluids; gastrointestinal 
stability 
 
 
 
1. Introduction 
The mucosal delivery of protein-based therapeutics, including vaccines, is one of the greatest 
challenges of today’s drug delivery research. For instance, in the case of the oral route, the harsh 
gastric and intestinal fluids pose severe obstacles to the stability of protein drugs (Lee, 2002). 
The first physicochemical barrier encountered in the gastro-intestinal (GI) tract is constituted by 
the stomach fluid: the pH in the stomach generally ranges from pH 1.0 to 2.5 in the normal fasted 
state condition (Evans et al., 1988). Furthermore, the stomach fluid is rich in the enzyme pepsin 
that constitutes a further biochemical barrier to proteins (Mahato et al., 2003). The intestine has a 
more neutral pH than the stomach, generally ranging from pH 6.3 to 7.5 (Evans et al., 1988). 
However, the intestinal fluid also represents a biochemical threat to the stability of therapeutic 
proteins, mainly due to the presence of pancreatic enzymes including trypsin and chymotrypsin 
(Mahato et al., 2003). In  recent years, systems based on the use of nanoparticulate carriers, 
encapsulating and hence protecting labile proteins through their passage in the GI tract, have 
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been investigated as possible options for the successful oral delivery of proteins (Kammona and 
Kiparissides, 2012).  
 
Virus-like particles (VLPs) are viral mimics, whose structure resembles the antigenic 
conformation and repetitive nature of the whole virus from which they are derived, yet are non-
infectious as they do not contain the viral genome (Jennings and Bachmann, 2008). VLPs differ 
from conventional nanoparticles, as the virus-derived protein antigen self-assembles into 
particles and hence the carrier is the antigen itself. Moreover, VLPs could be particularly suitable 
oral vaccine candidates, as it has been suggested that their highly compact structure could enable 
them to withstand the harsh GI environment (Herbst-Kralovetz et al., 2010; Huang et al., 2005). 
For example, Norwalk VLPs, derived from Norwalk virus, a major pathogen responsible for 
human gastro-enteritis, have been shown to be stable at low pH and are trypsin resistant (Ausar 
et al., 2006). 
 
Hepatitis B virus (HBV) is a major human pathogen. Chronic infection with HBV is associated 
with cirrhosis and primary liver cancer. The 42 nm HBV virion is formed by an external 
envelope surrounding an internal nucleocapsid, containing partially double-stranded DNA (Seitz 
et al., 2007). This internal nucleocapsid results from the self-assembly of the nucleocapsid 
protein, a 21 kDa protein called Hepatitis B core antigen (HBcAg): 180 or 240 HBcAg 
monomers are arranged into 30 or 34 nm icosahedral particles (Birnbaum and Nassal, 1990; 
Crowther et al., 1994). HBcAg VLPs can be produced as a recombinant protein in a variety of 
hosts, including plants (Huang et al., 2006; Mechtcheriakova et al., 2006; Sainsbury and 
Lomonossoff, 2008). HBcAg has been shown to induce potent B and T cell responses (Milich et 
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al., 1997, 1987). The very strong immunogenicity of HBcAg is believed to be related to its 
particulate and polymeric nature. Over the years, HBcAg has also earned the reputation of being 
an exceptionally promising carrier for foreign epitope sequences: the conjugation of such 
epitopes to particulate carriers allows high density and repetitive display of these epitopes on the 
surface of particles (Grgacic and Anderson, 2006). In addition, HBcAg is non-cytotoxic and is 
well tolerated in humans (Whitacre et al., 2009). 
 
In this study, HBcAg VLPs were produced in Nicotiana benthamiana using a transient 
expression system (Sainsbury and Lomonossoff, 2008). The aim of this study was to investigate 
both the chemical and physical stability of HBcAg VLPs upon exposure to several digestive and 
denaturing conditions simulating the variable conditions of the GI environment. Such studies are 
a prelude to the development of plant-HBcAg VLPs as a source of oral vaccines. 
 
2. Experimental Section 
2.1. Materials 
pEAQ-HT-HBcAgΔ176 (Peyret et al., 2015a; Sainsbury et al., 2009) is a construct designed to 
express the N-terminal 176 amino acids of HBcAg from the pEAQ transient expression vector. 
Monoclonal mouse HBcAg antibody 10E11 was purchased from Abcam (UK). Anti-mouse HRP 
conjugated antibody was obtained from Invitrogen (UK) or Amersham Bioscience (UK). 
Complete® Protease inhibitor tablets were purchased from Roche (UK), Miracloth from Merck 
(UK) and dialysis tubes from Spectrum Laboratories (Europe) or from Sigma -Aldrich (UK). 
SDS-NuPAGE gels bis-tris Mini, NuPAGE MOPS buffer and NuPAGE LDS Sample Buffer 
were purchased from Invitrogen (UK). β-Mercaptoethanol, Brilliant Blue R Concentrate, 
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3,3',5,5'-tetramethylbenzidine dihydrochloride (TMB) substrate were purchased from Sigma 
(UK). InstantBlue stain was bought from Expedon (UK), SuperSignal West Dura 
Chemiluminescent Substrate from Thermo Scientific (UK) and polyvinylidene fluoride (PVDF) 
membranes and Hyperfilm from Amersham (UK). Pepsin (Ph Eur) from porcine gastric mucosa 
and pancreatin (≥ 3× USP) from porcine pancreas were purchased from Sigma-Aldrich (UK). A 
full-length intestine was obtained from a freshly killed pig at a local abattoir (H. G. Blake, 
Costessey Ltd, Norwich, UK). The animal was processed under standard UK legislation for 
food-producing animals, the intestine extracted within a few hours of slaughter, transported 
intact to the laboratory on ice and the intestinal fluids extracted within a short time. 
 
2.2. HBcAg VLP expression, purification and characterization  
2.2.1. Plant growth, protein expression, extraction and detection techniques 
Nicotiana benthamiana plants were grown in a glasshouse at a fixed temperature of 25 ºC and 
used 3 to 4 weeks after pricking out. Suspensions of Agrobacterium tumefaciens (strain LBA 
4404) containing pEAQ-HT-HBcAgΔ176 were pressure-infiltrated into N. benthamiana leaves, 
using needle-less syringes as described previously 20. Infiltrated leaves were harvested 6 to 7 
days post-infiltration. Extraction of the protein from the leaves was performed at 4 ºC by 
homogenisation in three volumes of extraction buffer 1 (50 mM Tris-HCl, pH 7.25 : 150 mM 
NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), 0.1% w/v Triton X-100, 1 mM 
dithiothreitol and Complete® tablet) or extraction buffer 2 (10 mM Tris-HCl, pH 8.4 : 120 mM 
NaCl, 1 mM EDTA, 0.75% w/v sodium deoxycholate, 1 mM dithiothreitol and a Complete® 
Protease inhibitor tablet). The whole extract was then passed through a double layer of Miracloth 
and subsequently clarified by centrifugation at 12,000 x g in order to remove most plant cell 
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debris. All extractions were performed at 4 ºC. Plant expressed HBcAg VLPs were further 
purified by centrifugation of the protein extracts on 10-60% w/v sucrose density gradients 
prepared in 10 mM Tris-HCl pH 8.4, 120 mM NaCl. The gradients were centrifuged for 2.5 
hours at 4°C at either 40,000 rpm in a SW41Ti rotor or at 30,000 rpm in a Surespin 630 rotor. 
After centrifugation, the gradients were fractionated and the fractions dialysed against 10 mM 
Tris-HCl, 120 mM NaCl, pH 8.4 or phosphate buffer saline (PBS).  
 
2.2.2. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) - 
Coomassie Blue Staining 
Proteins were reduced and denatured by adding one volume of 3X LDS β-mercaptoethanol to 
two volumes of the samples. Samples were then heated to 100 ºC for 5 minutes. NuPAGE gels 
were run in 3-(N-morpholino)propanesulfonic acid (MOPS) buffer following the manufacturer’s 
instructions. After electrophoresis, the protein bands were visualised by addition of Coomassie 
blue-protein stain for at least 1 hour.  
 
2.2.3. Dot blot 
Three μL of each sample were spotted onto PDVF membranes using 10 μL tips. Membranes 
were left to dry for 30 minutes and then blocked with the blocking buffer (5% w/v dried milk, 
0.1% v/v Tween 20 in PBS) at 4 ºC overnight, before being incubated with monoclonal mouse 
HBcAg antibody, diluted 1:5000 in dot blot blocking buffer, for 2 hours. The membranes were 
then probed with anti-mouse horseradish peroxidase (HRP) conjugated secondary antibody, 
diluted 1:5000 in blocking buffer for a further 2 hours. Chemiluminescent HRP substrate was 
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used for the detection of the secondary antibody and captured on Hyperfilm (Sainsbury and 
Lomonossoff, 2008). 
 
2.2.4. Western blot  
SDS-PAGE gels were run as described above and the proteins transferred to PVDF membranes 
immediately after the electrophoresis. The membranes were blocked with the blocking buffer 
(1% w/v bovine serum albumin, 1% w/v casein, 0.05% v/v Tween 20 in PBS) at 4 ºC overnight 
and before being incubated with anti-mouse horseradish peroxidase (HRP) conjugated secondary 
antibody, diluted 1:5000 in blocking buffer for 2 hours. Chemiluminescent HRP substrate was 
used for the detection of the secondary antibody and captured on Hyperfilm (Peyret et al., 2015a; 
Sainsbury and Lomonossoff, 2008). 
 
2.2.5. Transmission Electron Microscopy (TEM)  
Samples diluted to an approximate concentration of 0.1 mg/mL were adsorbed onto hexagonal, 
plastic and carbon-coated copper grids, which were then washed three times with water. The 
grids were negatively stained with 2% w/v uranyl acetate before being imaged using a FEI 
Tecnal G2 20 Twin TEM with a built-in digital camera. 
 
2.2.6. Native agarose gel electrophoresis 
Agarose gels [1.2% w/v agarose in Tris/Borate/EDTA (3.03 g/L Tris-HCl, 5.5 g/L boric acid, 2 
mM EDTA)] were usually run in duplicate at 60 V for 90 minutes (Aljabali et al., 2012). One gel 
was stained with a 0.5 μg/mL solution of ethidium bromide for 30 minutes and then visualised 
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under UV light (wavelength = 302 nm). The other gel was stained with Brilliant Blue R 
Concentrate (Coomassie stain) for 30 minutes. 
 
2.3. HBcAg Stability in Simulated Gastric Fluid (SGF) 
2.3.1. HBcAg Stability in Simulated Gastric Fluid (SGF) without Pepsin 
VLP-rich fractions corresponding to 30 and 40 % w/v sucrose density bands were pooled 
together and were then diluted 1:5 with a solution of 80 mM HCl and 34 mM NaCl, resulting in a 
final pH of 1.2, matching SGF (British Pharmacopeia, 2012). The HBcAg solution in SGF was 
incubated at 37 °C for two hours. After incubation, it was layered on the top of a pH 1.2, 10 to 
45% w/v sucrose density step gradient. Alternatively, purified HBcAg VLP preparations were 
incubated at pH 1.2 for two hours as described previously. At the end of the two hour incubation, 
the pH of the sample was neutralised by initial dropwise addition of 1 M NaOH. The neutralising 
agent was switched to 0.1 M NaOH once the pH became closer to neutrality. The sample was 
then layered on the top of 10 mM Tris-HCl, 120 mM NaCl pH 8.4, 10 to 45% w/v sucrose 
density step gradient. As a control, the purified HBcAg particles were diluted in a 10 mM Tris-
HCl pH 8.4, 120 mM NaCl solution. After two hours incubation, the control sample was layered 
on the top of a 10 mM Tris-HCl pH 8.4, 10 to 45% w/v sucrose density step gradient. Following 
ultracentrifugation, fractions were collected from the sucrose gradients and analysed by 
Coomassie stained SDS-PAGE. If a precipitate formed at the bottom of the tube upon 
ultracentrifugation, it was re-suspended in 10 mM Tris-HCl, 120 mM NaCl pH 8.4 and analysed 
by Coomassie stained SDS-PAGE and Western blot. 
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For native agarose gel analysis, purified HBcAg VLPs in water were diluted 1:4 in each of the 
four acidic solutions: 10 mM HCl (pH 2) with 34 mM NaCl, 3.2 mM HCl (pH 2.5) with 34 mM 
NaCl, 1 mM HCl (pH 3) with 34 mM NaCl and 0.32 mM HCl (pH 3.5) with 34 mM NaCl. After 
two hours incubation, the four samples were loaded on agarose gel for electrophoresis. For TEM 
analysis, purified HBcAg VLPs in water were diluted 1:6 with a solution of 73 mM HCl to a 
final pH of 1.2. After two hours incubation at 37 °C, the pH was neutralised using aliquots of 
400 mM NaHCO3. The resulting sample was used for imaging.  
 
2.3.2. HBcAg Stability in Simulated Gastric Fluid (SGF) with Different Pepsin 
Concentrations 
Purified HBcAg VLPs were incubated at pH 1.2 with different concentrations of pepsin and a 
control with no pepsin (10, 3.2, 1, 0.5, 0.2, 0.1, 0.05, 0.01 and 0 mg/mL). After two hours 
incubation at 37 ºC, the samples were boiled to stop the enzymatic reaction and the proteins 
analysed by Western blotting.  
 
2.4. HBcAg Stability in in vitro and ex vivo Intestinal Fluid 
2.4.1. HBcAg Stability in Simulated Intestinal Fluid (SIF) 
Simulated intestinal fluid (SIF) with pancreatin was prepared by mixing 7.7 mL of 0.2 M 
NaOH with 25 mL of a solution containing 6.8 g of K2PO4 and 50 mL of water. Porcine 
pancreatin (≥ 3× USP), 333 mg, was then added. The pH was then adjusted to 6.8 and the 
volume diluted to 100 mL with water (British Pharmacopeia, 2012). SIF without pancreatin was 
prepared identically, but omitting the pancreatin. Before the stability experiment, a protease 
inhibitor tablet was diluted in 5 mL SIF without pancreatin. For Coomassie stained SDS-PAGE 
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and Western blot analysis, five samples of purified HBcAg diluted 1:19 in SIF were incubated at 
37 ºC for 240, 180, 120, 60 and 30 minutes. After the incubation the (10 x) protease inhibitor 
solution was diluted 1:9 in each digestion sample to stop the enzymatic reaction and samples 
were immediately cooled on ice. A 1:19 dilution of HBcAg in SIF without pancreatin was used 
as a positive control. A 1:19 dilution of water in SIF was used as a negative control. All samples 
were analysed by Coomassie stained SDS-PAGE and Western blotting. 
 
For dot blot analysis, the sample resulting from the digestion and the positive control were 
loaded onto six different 10-60% w/v sucrose density gradients. After ultracentrifugation, 
fractions from the sucrose gradients were collected and subjected to dot blot analysis.  
 
For native agarose gel electrophoresis, purified HBcAg was diluted 1:9 in SIF and incubated at 
37º C for 30, 60, 120, 180 or 240 minutes. After the incubation the protease inhibitor solution 
was diluted 1:9 in each sample corresponding to different incubation times and they were 
immediately cooled on ice. A 1:9 dilution of HBcAg in SIF without pancreatin was used as 
positive control and a 1:9 dilution of water in SIF was used as a negative control. All samples 
were used for ethidium bromide stained and Coomassie stained agarose gel electrophoresis. 
 
For TEM imaging, HBcAg was diluted 1:6 in SIF and the sample was incubated for 120 
minutes. The enzymatic reaction was then stopped by 1:9 dilution of protease inhibitor solution 
in the digestion sample. The sample was kept cool on ice. TEM imaging was carried out within 
two hours of the end of the incubation. 
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2.4.2. Ex Vivo HBcAg Stability in Natural Intestinal Fluid (natIF) 
Pig intestinal fluids were chosen as natural intestinal fluids (natIFs). The full-length intestine 
collected from the freshly killed animal was immediately transported to the laboratory and used 
for the collection of the luminal fluids. Four segments of approximately the same size from the 
proximal to the distal small intestine were divided and luminal fluid content was collected from 
each of the four segments separately. Small aliquots were made and frozen at – 80 ºC until use. 
Digestion experiments were conducted within ten weeks of collection of the fluids. For the SDS-
PAGE analysis, aliquots from the four different segments of the small intestine were thawed and 
the solid content was pelleted by centrifugation at 9300 x g for 10 minutes. Aliquots from the 
most proximal part of the intestine (i.e. duodenum) were centrifuged twice to separate the more 
viscous phase. The supernatants constituted the natural intestinal fluid (natIF) of this study. The 
four natIFs from the proximal to the distal small intestine are referred to as natIF 1, natIF 2, natIF 
3 and natIF 4 for the studies detailed below. Purified HBcAg aliquots were diluted 1:19 in each 
of the four natIFs and incubated at 37 ºC for 4 hours. At the end of the incubation, 1:3 dilutions 
of the four samples in water where made and then boiled to stop the enzymatic reaction. For a 
positive control, HBcAg aliquots were diluted 1:19 in PBS. Moreover, enzymatically inactive 
natIFs media were also used as positive controls: 1:3 dilutions of the natIFs in water and LDS β-
mercaptoethanol were boiled for 10 minutes and then cooled and purified HBcAg was added in 
the same ratio as in the digestion samples. Negative controls were also created by diluting the 
PBS in natIFs. All samples were then analysed by Coomassie staining SDS-PAGE and Western 
blot. 
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For dot blots, purified HBcAg aliquots were diluted 1:19 in the four natIFs and incubated at 37 
ºC for four hours. Then the proteolysis was stopped by the addition of 1:9 dilution of protease 
inhibitor solutions. For a positive control, HBcAg was diluted 1:19 in PBS. The control and the 
digestion samples were loaded onto five identical sucrose density gradients. After 
ultracentrifugation, fractions from the sucrose gradients were collected and analysed by dot blot 
using anti-HBcAg mouse monoclonal antibody. 
 
3. Results and Discussion 
3.1 Purification and analysis of plant-expressed HBcAg 
Sainsbury and Lomonossoff 14 showed that HBcAg could be expressed using the CPMV-HT 
system up to yields of approximately 1 g per kg of fresh weight tissue. Subsequently methods for 
the efficient purification of plant-expressed HBcAg VLPs have been developed (Peyret, 2015; 
Peyret et al., 2015a, 2015b). Here, the final purification of VLPs from the crude extract was 
carried out by sucrose density gradient ultracentrifugation. Seven fractions, each approximately 
corresponding to the density layers of sucrose and to the supernatant, were collected from the 
bottom of the tube (Figure 1. A) and analysed by Coomassie stained SDS-PAGE and Western 
blot (Figure 1. B left and right side, respectively). 
 
The Coomassie stained gel (Figure 1. B left side) showed a 20 kDa band, corresponding to the 
size of the 176 amino acid long monomeric HBcAg, in the 30, 40 and 50% w/v sucrose gradient 
fractions. The same band was, however, absent from the 60% w/v sucrose fraction. Most plant 
protein bands remained in the supernatant and in the 10 and 20% w/v sucrose fractions. The anti-
HBcAg Western blot (Figure 1. B right side) confirmed that the 20 kDa band, detected in the 30, 
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40 and 50 % w/v sucrose fractions in the Coomassie stained SDS-PAGE gel, corresponded to 
HBcAg. As expected, HBcAg was also detected in the original crude extract (lane E). In the 
HBcAg-rich lanes, it is also possible to notice a persistent 40 kDa band. The band was also 
observed by others and corresponds to HBcAg dimers, which are resistant to denaturation 
(Huang et al., 2006; Mechtcheriakova et al., 2006). Even larger size HBcAg multimeric 
structures have been detected in denaturing gel electrophoresis (Broos et al., 2007). Weaker 
bands of circa 15 kDa monomeric HBcAg and its dimer of 30 kDa can also be seen and they are 
possibly the result of partial enzymatic digestion of HBcAg by plant proteins. 
 
These results are in accordance with previous studies on HBcAg (Birnbaum and Nassal, 1990; 
Broos et al., 2007; Huang et al., 2006). Furthermore, when a sample containing the dialysed 30 
and 40% w/v sucrose gradient fractions was examined by native agarose gel (Figure 1. C), a 
clear band could be seen in the both the Coomassie- and ethidium bromide-stained gels. The two 
signals had the same electrophoretic mobility, suggesting that the VLP protein core, stained by 
the Coomassie, encapsidated nucleic acids, stained by ethidium bromide, consistent with 
previous reports (Newman et al., 2003). The presence of intact VLPs was further confirmed by 
TEM images (Figure 1. D) of the dialysed 30 and 40% w/v sucrose gradient fractions: intact 
VLPs were clearly visible and their diameter (circa 30 to 35 nm) matches the size documented in 
the literature (Lee and Tan, 2008; Wingfield et al., 1995). Overall, the Coomassie-stained SDS-
PAGE gel, the native agarose gel and the TEM showed a very high degree of purification of the 
VLPs upon ultracentrifugation. Approximately, a purity of > 90% could be estimated by 
visualization of the Coomassie-stained gel (Figure 1 B left side, lanes 4 and 5). 
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
3.2. HBcAg in vitro and ex-vivo stability in gastro-intestinal media  
A previous study on plant-expressed HBcAg VLPs showed that oral administration of plant 
extracts containing HBcAg elicited only poor immunogenicity in mice and it was speculated that 
this could have been due to the gastric degradation or the physical disassembly of the antigen 
(Huang et al., 2006). Hence, the stability of plant-expressed HBcAg VLPs in gastric and 
intestinal conditions was investigated here: each experiment consisted of incubation of purified 
VLPs in the bio-relevant media, followed by a post-incubation assessment of their physical and 
chemical stability. 
 
3.2.1. HBcAg Stability in Simulated Gastric Fluid (SGF) 
Initially the stability of plant-expressed HBcAg VLPs was investigated at the acidic pH of the 
SGF (pH 1.2). Three experiments were carried out (Figure 2. A, B and C): in one case purified 
HBcAg VLPs were incubated for 2 hours at pH 8.4 and then separated by sucrose gradient 
ultracentrifugation, with fractions of the gradient prepared at the same pH (control, Figure 2. A). 
In the second case HBcAg VLPs were incubated for 2 hours at pH 1.2 and then sample separated 
by sucrose gradient ultracentrifugation, set up in a way to maintain the pH of the sucrose 
fractions consistent with the incubation pH (Figure 2. B). In the third case, HBcAg VLPs were 
incubated for 2 hours at pH 1.2, then, following neutralization, the sample was separated by 
sucrose gradient ultracentrifugation, with sucrose fractions prepared at pH 8.4 (Figure 2. C). 
 
SDS-PAGE followed by Coomassie Blue staining of the collected fractions shows that the 
acidic pH of the SGF did not chemically degrade the HBcAg polypeptide, which ran as a circa 
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20 kDa protein band (Figure 2. B), as in the control (Figure 2. A). HBcAg migrated towards the 
bottom of the density gradient in the control sample incubated at pH 8.4 (Figure 2. A), as 
indicated by the presence of the 20 kDa band only in the lanes corresponding to 30 and 40% w/v 
sucrose fractions (lanes 6 to 8), suggesting physically intact VLPs. However, in the sample 
incubated in SGF and analysed on a sucrose gradient at pH 1.2 (Figure 5. B), the 20 kDa band 
could be seen in most of the fractions (lanes 1 to 8). This result clearly suggests that the capsid 
structure of HBcAg VLP exhibits a certain degree of physical instability on exposure to the 
acidic conditions. In the case of the sample of VLPs initially exposed to pH 1.2 and then 
neutralized and separated by ultracentrifugation containing fractions at pH 8.4, the Coomassie 
stained gel (Figure 2. C) showed that a 20 kDa protein band, corresponding to HBcAg, was not 
present in any of the gradient fractions. 
 
However, a precipitate was visible at the bottom of the tube used for the ultracentrifugation of 
the sample. This precipitate was re-suspended and analysed by SDS-PAGE, revealing the 
presence of a band of a similar size to HBcAg, which reacted with anti-HBcAg antibodies in a 
Western blot (Fig. 2C). The fact that HBcAg was not found in any of the fractions of the gradient 
but in a precipitate at the bottom of the tube indicates that HBcAg was not present as intact VLP, 
nor as a disassembled monomeric or multimeric form but as a high molecular weight aggregate. 
 
For a final characterisation of HBcAg in SGF without pepsin, purified HBcAg particles were 
incubated in SGF at pH 1.2 for two hours and then the acidity was neutralised. This sample was 
used for TEM imaging. The TEM image (Figure 2. D) showed that the typical HBcAg VLPs 
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detected in the control sample could not be found in the acidified and neutralised sample; instead 
aggregates could be seen, probably representing aggregated VLPs.  
 
 
These results taken together indicate that the HBcAg polypeptide is chemically stable at pH 
1.2. However, the VLPs tend to partially disassemble at this pH (Figure 2. B). When the pH is 
raised the dissociated subunits tend to form aggregates rather than reassemble into VLPs. (Figure 
2. C and D). These results demonstrate that HBcAg VLPs are likely to be physically unstable in 
the stomach environment of humans. Although it is possible that the low pH would not cause a 
complete disassembly of the capsid, the subsequent passage to a more neutral pH in the intestine 
would induce aggregation. However, the actual pH of human gastric fluid in fasted state is not 
strictly 1.2, but is in the range between 1.0 and 2.5 (Evans et al., 1988). Hence, to better delineate 
HBcAg VLP physical stability in gastric conditions, the threshold pH for HBcAg VLP stability 
was investigated using native agarose gel electrophoresis. 
 
The ethidium bromide-stained agarose gel (Figure 3. - left side) showed the presence of 
nucleic acids trapped in the wells of samples incubated at pH 2.0 (lane 1) and pH 2.5 (lane 2). 
The sample incubated at pH 3.0 (lane 3) showed a smear of nucleic acids in the gel, while a 
discrete band was visible in the sample incubated at pH 3.5 (lane 4). The Coomassie stained gel 
(Figure 3. - right side) confirmed the presence of a protein smear in the sample incubated at pH 3 
(lane 3); furthermore, a protein band could be seen in the sample incubated at pH 3.5 (lane 4): 
this band showed an identical electrophoretic migration to the respective lane in the ethidium 
bromide gel. These results suggest that HBcAg VLP quaternary structure is physically stable 
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upon incubation in acid at pH 3.5 for two hours but is only partially stable when incubated at pH 
3.0. Considering the previous finding that HBcAg VLPs appeared to partially dissociate and then 
aggregate upon acidification and subsequent neutralisation (Figure 2. C and D), it is likely that 
HBcAg VLPs treated at pH 2.0 and pH 2.5 underwent a similar process upon neutralisation by 
the Tris/Borate/EDTA (TBE) buffer present in the gel, leading to observed trapping in the wells.  

This result is in accordance with Newman et al 25: in that case, it was shown that bacterially 
expressed HBcAg incubated at pH 2.0 for only 30 minutes was unstable and it remained blocked 
in the well (Newman et al., 2003). Overall, in the current study, the native agarose gel 
electrophoresis revealed that this complete loss of the physical stability upon incubation of 
HBcAg for two hours in acid and further neutralisation occurs at pH values below 3 to 3.5 
(Figure 3). The fact that the VLP particulate structure was lost upon incubation in media at pH 
values lower than pH 3 to 3.5 suggests that HBcAg would be unstable in the fasted gastric 
environment, i.e. pH 1 to pH 2.5 (Evans et al., 1988). However, it was reported that the average 
stomach pH can remain > 3.5 for the first three hours after a meal (Kalantzi et al., 2006). 
Therefore, it could be expected that the VLP structure could be physically stable at the pH of the 
fed stomach. 
 
The stability of purified plant-expressed HBcAg was also evaluated after 2 hours incubation in 
SGF in the presence of the enzyme pepsin. The British Pharmacopoeia (2012) formula of SGF 
has a fixed 3.2 g/L pepsin (Ph Eur) concentration; however variations of pepsin activity up to 
four orders of magnitude have been reported in humans (Gomes et al., 2003). For this reason it 
was decided to incubate several aliquots of HBcAg in SGF at pH 1.2 containing pepsin at 
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concentrations ranging from 10 g/L to 0.01 g/L. After two hours incubation, the samples were 
analysed by Western blotting (Figure 4.). The Western blot shows that the 20 kDa band, present 
in the control and corresponding to intact HBcAg, was absent in the sample of HBcAg incubated 
in SGF containing 3.2 g pepsin/L, i.e. the concentration specified in the British Pharmacopoeia 
(2012). Furthermore, some digestion of HBcAg occurred at all concentrations of pepsin. For 
concentrations of pepsin ≥ 0.5 g/L (lanes 2 to 5), no anti-HBcAg signal could be detected; 
however, for concentrations of pepsin ≤ 0.2 g/L (lanes 7 to 10) a circa 14 kDa band of anti-
HBcAg immunoreactivity could be visualised. Only when the concentration of pepsin was as low 
as 0.01 g/L (lane 10) was a detectable amount of 20 kDa HBcAg present.  
 
This result suggests that HBcAg is extremely sensitive to chemical digestion by pepsin, not 
only at the pharmacopoeial pepsin concentration of SGF, but at thousands-fold lower 
concentrations. Wang et al (2015) have recently shown that there is a good correlation between 
the stability of peptides in SGF and native human gastric fluids. Hence, according to the data 
presented here, it is likely that HBcAg, aside from being physically unstable, would also be 
highly digested in the gastric fluid in vivo. 

3.2.2 HBcAg in Intestinal Fluids: An In Vitro and Ex Vivo Stability Approach 
The second barrier that HBcAg will encounter upon oral administration is the harsh 
environment of the small intestine: it contains several enzymes, including trypsin and 
chymotrypsin, which could digest a protein antigen. The ability of HBcAg to withstand the 
intestinal digestive environment was investigated from two angles: firstly HBcAg was incubated 
in a conventional in vitro model of intestinal fluid containing pancreatic enzymes. Then a more 
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bio-relevant study was carried out using natural small intestinal fluids from pig, in order to more 
closely mimic the in vivo scenario in humans. Similar trends in the degradation of peptides in 
native human intestinal fluids, native pig intestinal fluids and simulated human intestinal fluids 
were observed by Wang et al (2015), validating the approach used. 
 
The results of the experiments examining the chemical and physical stability of HBcAg VLPs 
incubated in SIF are shown in Figure 5. The Coomassie stained gel (Figure 5. A) shows that the 
circa 20 kDa band, seen in the positive control (lane 1) and corresponding to HBcAg, slightly 
overlaps with a much fainter band of the same size in the negative control (lane 2). For this 
reason, careful consideration is required when interpreting these results. The different protein 
bands visible in the negative control are probably pancreatic proteins and enzymes. At all 
incubation times in SIF, HBcAg was partially digested to give predominantly a circa 17 kDa 
protein band. The intensity of this band seems to increase proportionally with the incubation time 
in SIF. These results were confirmed by the Western blot, which shows that the strongest anti-
HBcAg signal in the samples incubated in SIF (lanes 3 to 7) was the circa 17 kDa band, though a 
series of HBcAg-specific bands of intermediate sizes between the full-length and the 17 kDa 
version were also present in smaller quantities. As expected a circa 20 kDa band, corresponding 
to undigested HBcAg is seen in the positive control (lane 1) and no bands are present in the 
negative control (lane 2). Considering that the anti-HBcAg mouse monoclonal primary antibody 
used has specificity for the first 10 amino acids at the N-terminal, it is evident that the digestion 
is expected to have only occurred at the C-terminus. In contrast, digestion at the N-terminal 
would have resulted in loss of affinity of HBcAg to this given antibody, resulting in a lack of 
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immunoreactivity. The above results demonstrated that HBcAg was digested to a smaller protein 
after exposure to SIF. 
 
To determine whether the major digestion product (17 kDa) was in the form of VLPs, the 
digested samples were examined on sucrose gradients. Figure 5. C, D and E illustrate the effect 
of the incubation of HBcAg in SIF with pancreatin on its physical stability. The dot blot (Figure 
5. C) represents the HBcAg sedimentation upon ultracentrifugation of the samples undergoing 
the proteolytic treatment. Irrespective of the incubation time in SIF with pancreatin, most 
HBcAg immunoreactivity could be visualised in dots corresponding to the 30 and 40% w/v 
sucrose fractions, as in the undigested VLP positive control. This result suggests that HBcAg 
maintained its particulate form after digestion. This was also confirmed by native agarose gel 
electrophoresis (Figure 5. D). HBcAg incubated in SIF (lanes 2 to 7) showed electrophoretic 
migration almost identical to that of the untreated VLP of the control sample (lane 1). Finally, 
TEM imaging (Figure 5. E) showed that VLPs were still present after incubation of HBcAg in 
SIF with pancreatin for 120 minutes. These results taken together indicate that HBcAg was 
partially digested upon treatment in SIF; however the digestion did not seem to interfere with 
physical stability of the VLPs. 
 
 
The pancreatin present in the SIF contains several pancreatic proteases, including trypsin, 
chymotrypsin and elastase, which could potentially digest antigens. Interestingly, it was reported 
in a virology study, that HBcAg, expressed in Xenopus oocytes, was partially digested into 
smaller proteins upon incubation in trypsin: the main residue was a circa 17 kDa protein, but 
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several intermediate forms ranging between 17 and 21 kDa were also detected, corresponding to 
different cleavage sites for trypsin at the C-terminus. The trypsin digestion did not seem to affect 
the particle assembly (Seifer and Standring, 1994). It is worth remembering that HBcAg bears in 
its monomeric structure a C-terminal tail arginine-rich domain. This domain is not essential for 
the assembly and stabilisation of the monomers into a VLP (Birnbaum and Nassal, 1990; Zheng 
et al., 1992). Intriguingly, it was demonstrated that the trypsin digests only these C-terminus 
sequences, which were “non-essential” for the particle assembly. The authors suggested that 
these C-terminal regions are accessible to the enzymatic attack, while other possible cleavage 
sites are relatively sequestered inside the VLP structure. Moreover, it was shown that the 
maximal trypsin cleavage was achieved after only 8 minutes of incubation (Seifer and Standring, 
1994). The results obtained in SIF with pancreatin strongly suggest that the main pancreatic 
enzyme involved in the digestion of HBcAg is trypsin. In fact the intestinal bio-relevant media 
used determined a similar pattern of digestion to that indicated in the study, described by Saifer 
and Standring (Seifer and Standring, 1994). 
 
These results suggest that HBcAg VLPs, though partially digested, could still withstand the 
intestinal environment while maintaining the particulate morphology and immunogenicity. In 
fact, it was found that all the major epitopes mediating T- and B-cell responses are not found in 
the C-terminal arginine rich region (Vanlandschoot et al., 2003), which is digested by the trypsin. 
 
Despite the fact that pancreatic enzymes are the main proteases in the intestine, it has been 
recently reported that pancreatic proteases only partially contribute to the total intestinal 
enzymatic activity in animal models (Reuter et al., 2009). Therefore, the stability of HBcAg in 
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natural intestinal fluid (natIF) of the pig was investigated, in order to complement the in vitro 
model. The whole pig small intestine was divided into four parts of approximately same length 
and natIFs were collected from the resulting four sections and named natIF 1, natIF 2, natIF 3 
and natIF 4 from the proximal to the distal regions. For evaluating the extent of digestion, 
HBcAg VLPs were incubated in each of these natural media at 37 ºC for 4 hours and the fate of 
HBcAg was subsequently evaluated. 
 
Figure 6. shows the Coomassie stained SDS-PAGE, Western blot and dot blot of sucrose 
gradient fractions. As a negative control, natIF diluted in water was used. Positive controls, 
including a dilution of HBcAg in PBS and a dilution in previously boiled, and thus enzymatically 
inactive, natIFs were used. The Coomassie stained gel (Figure 6. A) showed a faint 20 kDa band 
corresponding to HBcAg in the positive control in PBS (lane 1). However, it was difficult to 
identify HBcAg in the other samples containing natIFs due to the very high content of proteins of 
various sizes present in these media and also visible in the negative control. Nevertheless, the 
Western blot of the same samples (Figure 6. B) showed that anti-HBcAg immunoreactivity was 
detected at circa 20 kDa in all positive controls where natIFs had been previously inactivated 
(lanes 2 to 5). In contrast, for the actual digestion samples where active natIFs were present 
(lanes 6 to 9), HBcAg was mainly visible as a circa 16-17 kDa band. The intensity of the band 
was the highest in natIF 1 (lane 6) and reached a minimum in natIF 2 (lane 7), then it gradually 
increased in natIF 3 (lane 8) and natIF 4 (lane 9). In natIF 4 a weak 20 kDa band was also 
present, probably corresponding to intact HBcAg. As expected, no bands were seen in the 
negative controls (lanes 11 to 14). 
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In a similar experiment samples were not boiled, so that the VLPs could maintain their native 
physical structure. However, the enzymatic reaction was stopped at the end of the digestion study 
by adding a protease inhibitor solution. Sucrose density gradient ultracentrifugation was then 
carried out in parallel for the four samples, corresponding to the digestion of HBcAg in the four 
natIFs, and for the control sample of HBcAg in PBS. After ultracentrifugation, fractions were 
collected and analysed by dot blot. Figure 6. C shows that in the positive control anti-HBcAg 
immunoreactive dots were found mainly in the 30 and 40 % w/v sucrose fractions, as typical for 
intact HBcAg VLPs. For samples digested in the natIFs, HBcAg was still detected mainly in the 
30 and 40% w/v sucrose density fractions; however, some immunoreactivity was also present in 
the less dense fractions of the gradient.  
 
These results suggest that, despite the fact that the natural intestinal fluids have a much wider 
pool of proteases than just the pancreatic proteases used in vitro (Reuter et al., 2009), the main 
product of HBcAg digestion appears to be the same, i.e. a 16-17 kDa immunogenic protein still 
assembled as a VLP. In terms of physical stability of HBcAg in pig small intestinal fluids, the 
detection of some minor anti-HBcAg signal in the less dense fractions of the gradient suggested 
that partial disassembly took place upon incubation of HBcAg natIFs. However most of the 
immunoreactivity was still detected in the 30 and 40% w/v sucrose gradient fractions, where 
usually intact VLPs are found. It can be concluded that HBcAg appeared chemically unstable 
upon incubation in pig intestinal fluids. However, these data also suggest that the principal 
digestion products were still immunoreactive and that HBcAg was still mainly present as a VLP. 
The use of the pig natIFs here was part of a preliminary study to explore their use in the 
evaluation of the intestinal fate of administered pharmaceutical products. Here, the results of the 
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pig natIF experiments were in line with those of the more conventional SIF experiments, 
suggesting that this approach has merit and agreeing with the previous work in this area by Wang 
et al (2015). 
 
4. Conclusions 
This study aimed to gain a better understanding of the stability of purified HBcAg in the 
gastro-intestinal (GI) tract: it was demonstrated that HBcAg VLPs were highly physically and 
chemically unstable in simulated human gastric media. Moreover, it was shown that HBcAg was 
digested in simulated human intestinal fluid (SIF) and ex-vivo pig intestinal fluids, but 
surprisingly the main digested form of HBcAg maintained the particulate three-dimensional 
structure and the most antigenic epitopes. This offers an important prediction about the stability 
of HBcAg administered orally and can help interpret previous findings: previous research 
showed that HBcAg could elicit only weak immunogenicity upon oral administration in mice, 
hence it was speculated that exposure to the gastric environment could have resulted in either 
major chemical degradation or particulate disassembly before the VLP could enter into contact 
with the mucosal surfaces of the intestine (Huang et al., 2006). This assumption is supported by 
the current work, which indicates that HBcAg gastric instability, both in terms of chemical 
digestion and physical disassembly, can constitute a major obstacle to HBcAg oral delivery. The 
measured stability of HBcAg in SGF, SIF and natIFs in this study is likely to closely reflect its 
human in vivo stability, as it has recently been demonstrated that trends of digestion of peptide 
drugs in these media correlated well with their digestion in human fluids. The current findings 
are an important step towards understanding the complex oral immunogenicity of HBcAg. 
However, the current results also suggest that if the gastric instability could be bypassed, HBcAg 
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could circulate through the human small intestine withstanding major degradation. Our current 
work is investigating this with a view to developing a patient-friendly orally-administered 
formulation which will protect the HBcAg from the harsh conditions in the stomach but release it 
intact in the intestine where it can exert its immunogenic effect. 
 
Finally, in this paper a novel methodology to investigate the oral stability of VLPs has been 
put forward: the fate of the VLP was evaluated not only in terms of chemical digestion of the 
primary structure, but also in terms of the stability of the three-dimensional quaternary structure.  
 
Declaration 
The authors declare no competing financial interest. 
 
Acknowledgements 
The authors would like to thank the University of East Anglia and the John Innes Centre (both 
Norwich Research Park) for funding this work as a PhD studentship for AB. 
References 
Aljabali, A.A.A., Shukla, S., Lomonossoff, G.P., Steinmetz, N.F., Evans, D.J., 2012. CPMV-
DOX Delivers. Mol. Pharm. 10, 3–10. 
Ausar, S.F., Foubert, T.R., Hudson, M.H., Vedvick, T.S., Middaugh, C.R., 2006. Conformational 
stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J. 
Biol. Chem. 281, 19478–88. doi:10.1074/jbc.M603313200 
Birnbaum, F., Nassal, M., 1990. Hepatitis B virus nucleocapsid assembly: primary structure 
requirements in the core protein. J. Virol. 64, 3319–3330. 
27 
 
Broos, K., Vanlandschoot, P., Maras, M., Robbens, J., Leroux-Roels, G., Guisez, Y., 2007. 
Expression, purification and characterization of full-length RNA-free hepatitis B core 
particles. Protein Expr. Purif. 54, 30–37. 
Crowther, R.A., Kiselev, N.A., Böttcher, B., Berriman, J.A., Borisova, G.P., Ose, V., Pumpens, 
P., 1994. Three-dimensional structure of hepatitis B virus core particles determined by 
electron cryomicroscopy. Cell 77, 943–950. 
Evans, D.F., Pye, G., Bramley, R., Clark, A.G., Dyson, T.J., Hardcastle, J.D., 1988. 
Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 29, 
1035–41. 
Gomes, R.A.D.S., Batista, R.P., de Almeida, A.C., da Fonseca, D.N., Juliano, L., Hial, V., 2003. 
A fluorimetric method for the determination of pepsin activity. Anal. Biochem. 316, 11–14. 
doi:10.1016/S0003-2697(03)00025-3 
Grgacic, E.V.L., Anderson, D.A., 2006. Virus-like particles: passport to immune recognition. 
Methods 40, 60–5. doi:10.1016/j.ymeth.2006.07.018 
Herbst-Kralovetz, M., Mason, H.S., Chen, Q., 2010. Norwalk virus-like particles as vaccines. 
Expert Rev. Vaccines 9, 299–307. doi:10.1586/erv.09.163.Norwalk 
Huang, Z., Elkin, G., Maloney, B.J., Beuhner, N., Arntzen, C.J., Thanavala, Y., Mason, H.S., 
2005. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk 
viruses. Vaccine 23, 1851–1858. 
Huang, Z., Santi, L., LePore, K., Kilbourne, J., Arntzen, C.J., Mason, H.S., 2006. Rapid, high-
level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. 
Vaccine 24, 2506–2513. 
Jennings, G.T., Bachmann, M.F., 2008. The coming of age of virus-like particle vaccines. Biol. 
28 
 
Chem. 389, 521–536. doi:10.1515/BC.2008.064 
Kalantzi, L., Goumas, K., Kalioras, V., Abrahamsson, B., Dressman, J.B., Reppas, C., 2006. 
Characterization of the human upper gastrointestinal contents under conditions simulating 
bioavailability/bioequivalence studies. Pharm. Res. 23, 165–76. doi:10.1007/s11095-005-
8476-1 
Kammona, O., Kiparissides, C., 2012. Recent Advances in Nanocarrier-based Mucosal Delivery 
of Biomolecules. J. Control. Release 161, 781–794. doi:10.1016/j.jconrel.2012.05.040 
Lee, H.J., 2002. Protein drug oral delivery: the recent progress. Arch. Pharm. Res. 25, 572–84. 
Lee, K.W., Tan, W.S., 2008. Recombinant hepatitis B virus core particles: association, 
dissociation and encapsidation of green fluorescent protein. J. Virol. Methods 151, 172–80. 
doi:10.1016/j.jviromet.2008.05.025 
Mahato, R.I., Narang, A.S., Thoma, L., Miller, D.D., 2003. Emerging trends in oral delivery of 
peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20, 153–214. 
Mechtcheriakova, I.A., Eldarov, M.A., Nicholson, L., Shanks, M., Skryabin, K.G., Lomonossoff, 
G.P., 2006. The use of viral vectors to produce hepatitis B virus core particles in plants. J. 
Virol. Methods 131, 10–15. 
Milich, D.R., Chen, M., Schödel, F., Peterson, D.L., Jones, J.E., Hughes, J.L., 1997. Role of B 
cells in antigen presentation of the hepatitis B core. Proc. Natl. Acad. Sci. U. S. A. 94, 
14648–53. 
Milich, D.R., McLachlan, A., Moriarty, A., Thornton, G.B., 1987. Immune response to hepatitis 
B virus core antigen (HBcAg): localization of T cell recognition sites within 
HBcAg/HBeAg. J. Immunol. 139, 1223–31. 
Newman, M., Suk, F.-M., Cajimat, M., Chua, P.K., Shih, C., 2003. Stability and Morphology 
29 
 
Comparisons of Self-Assembled Virus-Like Particles from Wild-Type and Mutant Human 
Hepatitis B Virus Capsid Proteins. J. Virol. 77, 12950–12960. doi:10.1128/jvi.77.24.12950-
12960.2003 
Peyret, H., 2015. A protocol for the gentle purification of virus-like particles produced in plants. 
J. Virol. Methods 225, 59–63. 
Peyret, H., Gehin, A., Thuenemann, E.C., Blond, D., El Turabi, A., Beales, L., Clarke, D., 
Gilbert, R.J.C., Fry, E.E., Stuart, D.I., 2015a. Tandem Fusion of Hepatitis B Core Antigen 
Allows Assembly of Virus-Like Particles in Bacteria and Plants with Enhanced Capacity to 
Accommodate Foreign Proteins. PLoS One 10. 
Peyret, H., Stephen, S.L., Stonehouse, N.J., Rowlands, D.J., 2015b. History and Potential of 
Hepatitis B Virus core as a VLP vaccine platform, in: Y, K., P, P. (Eds.), Viral 
Nanotechnology. Boca Raton: CRC Press, pp. 177–186. 
Reuter, F., Bade, S., Hirst, T.R., Frey, A., 2009. Bystander protein protects potential vaccine-
targeting ligands against intestinal proteolysis. J. Control. Release 137, 98–103. 
doi:10.1016/j.jconrel.2009.03.015 
Sainsbury, F., Lomonossoff, G.P., 2008. Extremely High-Level and Rapid Transient Protein 
Production in Plants without the Use of Viral Replication. Plant Physioliogy 148, 1212–
1218. doi:10.1104/pp.108.126284 
Sainsbury, F., Thuenemann, E.C., Lomonossoff, G.P., 2009. pEAQ: versatile expression vectors 
for easy and quick transient expression of heterologous proteins in plants. Plant Biotechnol. 
J. 7, 682–693. 
Seifer, M., Standring, D.N., 1994. A protease-sensitive hinge linking the two domains of the 
hepatitis B virus core protein is exposed on the viral capsid surface. J. Virol. 68, 5548–
30 
 
5555. 
Seitz, S., Urban, S., Antoni, C., Böttcher, B., 2007. Cryo-electron microscopy of hepatitis B 
virions reveals variability in envelope capsid interactions. EMBO J. 26, 4160–7. 
doi:10.1038/sj.emboj.7601841 
Vanlandschoot, P., Cao, T., Leroux-Roels, G., 2003. The nucleocapsid of the hepatitis B virus: a 
remarkable immunogenic structure. Antiviral Res. 60, 67–74. 
Wang, J., Yadav, V., Smart, A.L., Tajiri, S., Basit, A.W., 2015. Toward Oral Delivery of 
Biopharmaceuticals: An Assessment of the Gastrointestinal Stability of 17 Peptide Drugs. 
Mol. Pharm. 12, 966–973. doi:10.1021/mp500809f 
Whitacre, D., Lee, B., Milich, D.R., 2009. Use of hepadnavirus core proteins as vaccine 
platforms. Expert Rev. Vaccines 8, 1565–1573. doi:10.1586/erv.09.121.Use 
Wingfield, P.T., Stahl, S.J., Williams, R.W., Steven, A.C., 1995. Hepatitis core antigen produced 
in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid 
assembly. Biochemistry 34, 4919–32. 
Zheng, J., Schödel, F., Peterson, D.L., 1992. The structure of hepadnaviral core antigens. 
Identification of free thiols and determination of the disulfide bonding pattern. J. Biol. 
Chem. 267, 9422–9. 
 
  
31 
 

 
Figure 1. HBcAg purification and characterization. (A) Diagram of sucrose gradient (7 fractions 
from the supernatant to 60% w/v sucrose); (B) Coomassie stained SDS-PAGE (left side) and 
Western blot (right side) of the fractions. The lanes arrangement was as follows: crude extract 
(lane E), supernatant (lane S), 10 to 60% w/v sucrose fractions (lane 1 to lane 6). (C) Native 
agarose gel electrophoresis - stained with Coomassie stain (lane 1) or with ethidium bromide 
(lane 2); and (D) TEM images of Purified HBcAg samples, dialysed from 30 and 40% w/v 
sucrose gradient fractions.  
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
 
Figure 2. HBcAg stability in simulated gastric fluid (without pepsin). (A) Purified HBcAg was 
incubated in the control (pH 8.4) and then after 2 hours incubation, separated by density gradient 
ultracentrifugation at pH 8.4 - supernatant (lanes 1 to 3), 10 to 45% w/v sucrose fractions (lanes 
4 to 8). (B) Purified HBcAg was incubated in SGF (pH 1.2) and then, after 2 hours incubation, 
separated by density gradient ultracentrifugation at pH 1.2 - supernatant (lanes 1 to 3), 10 to 45% 
w/v sucrose fractions (lanes 4 to 8). (C) Purified HBcAg was incubated in SGF (pH 1.2) and then 
after 2 hours incubation, the pH was neutralized and the sample separated by density gradient 
ultracentrifugation at pH 8.4 - supernatant (lane 1), 10 to 45% w/v sucrose fractions (lanes 2 to 
7); precipitate (lane P); at the right side of the image the same precipitate was examined by 
Western blot. (D) TEM images: a control HBcAg sample (left image), an HBcAg sample after 2 
hours acidification in SGF and subsequent neutralisation (right image). 
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Figure 3. HBcAg VLP stability in different acidic conditions. HBcAg was incubated at different 
pH and the samples run in an ethidium bromide stained native agarose gel (left) and an identical 
Coomassie stained gel (right): pH 2 (lane 1); pH 2.5 (lane 2); pH 3 (lane 3) and pH 3.5 (lane 4). 

Figure 4. HBcAg digestion in SGF (with pepsin). HBcAg was incubated for two hours in SGF 
containing different concentrations of pepsin. The digested samples were then analysed by 
Western blot: SGF without pepsin (lane 1 and lane 6); 10 g/L pepsin (lane 2); 3.2 g/L pepsin 
(lane 3); 1 g/L pepsin (lane 4); 0.5 g/L pepsin (lane 5); 0.2 g/L pepsin (lane 7); 0.1 g/L pepsin 
(lane 8); 0.05 g/L pepsin (lane 9) and 0.01 g/L pepsin (lane 10). 
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Figure 5.  HBcAg chemical stability in SIF. Aliquots of purified HBcAg were incubated in SIF 
with pancreatin for different time intervals. All the resulting digestion samples were analysed by 
different techniques. (A) Coomassie stained SDS-PAGE and (B) Western blot: positive control 
(lane 1); negative control (lane 2); 30 minutes digestion (lane 3); 60 minutes (lane 4); 120 
minutes (lane 5); 180 minutes (lane 6); 240 minutes (lane 7). (C) Dot blot of sucrose gradient 
fractions: percentages indicate the approximate concentration of the sucrose density fraction (S = 
supernatant), while incubation times are listed vertically; (P = positive control). (D) Native 
agarose gel of the digested samples : positive control (lane 1); negative control (lane 2); 30 
minutes (lane 3); 60 minutes (lane 4); 120 minutes (lane 5); 180 minutes (lane 6); 240 minutes 
(lane 7). (E) TEM image of HBcAg incubated in SIF with pancreatin for two hours. 
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Figure 6. Ex vivo HBcAg stability in pig intestinal fluids. Stability studies were carried out in 
four NatIFs collected from pig, named natIF 1, natIF 2, natIF 3, natIF 4 from the proximal to the 
distal small intestine, respectively. HBcAg was incubated in each of the aforementioned media at 
37 ºC for four hours. (A) and (B) represent the Coomassie stained SDS-PAGE and Western blot 
(monoclonal antibody), respectively. The two gels were run identically: HBcAg in PBS (lane 1); 
HBcAg in inactive natIF 1 to natIF 4 (lanes 2 to 5, respectively); HBcAg in natIF 1 to natIF 4 
(lanes 6 to 9); empty lane (lane 10); PBS in natIF 1 to natIF 4 (lanes 11 to 14). (C) shows the dot 
blot (monoclonal antibody) of fractions collected from sucrose density gradient 
ultracentrifugation of different HBcAg samples incubated in each of the aforementioned natIFs. 
The sucrose concentrations corresponding to density fractions collected are indicated 
horizontally; the incubation samples analysed are indicated vertically. P = positive control 
(HBcAg in PBS); S = supernatant. 
 
